Alvogen, Inc.
Alvogen, Inc. received $0 in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 100.0% from $227.7M the year before, and $284.8M since FY2022. Its largest customer is the Department of Health and Human Services.
See 1 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- LJNNGDV77Y98
- CAGE code
- 6K8D6
- Headquarters
- Pine Brook, NJ
- Business size
- Other Than Small Business
- Parent company
- Alvogen Group Inc. (UEI M46VKH1YNMV7)
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | $0 | $284.8M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | $0 | $284.8M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $284.8M |
| 6515 | Medical and Surgical Instruments, Equipment, and Supplies | $2K |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75A50325F80013 | Department of Health and Human Services OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS. | $227.7M | Jun 29, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| SPE2D026F0002 | Department of Defense 8511678232!OTHER MEDICAL | $94 | Oct 1, 2025 |
| 75A50325F80013 | Department of Health and Human Services OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS. | $227.7M | Jun 29, 2025 |
| SPE2D025F0008 | Department of Defense 8510933584!OTHER MEDICAL | $2K | Oct 3, 2024 |
| 75A50324F63003 | Department of Health and Human Services OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE) | $57.1M | Sep 19, 2024 |
| SPE2D024F0004 | Department of Defense 8510197261!OTHER MEDICAL | $1K | Oct 7, 2023 |
| SPE2D323F198X | Department of Defense 4562150132!OXYCODONE HCL 5 MG TABLET | $51 | Sep 11, 2023 |
| SPE2D323F100D | Department of Defense 4561648522!OXYCODONE HCL 5 MG TABLET | $68 | Jul 27, 2023 |
| SPE2D323F001F | Department of Defense 4561223209!OXYCODONE HCL 5 MG TABLET | $34 | Jun 7, 2023 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.